Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07816809

Phage-based Control and Limitation of Pathobionts for Microbiome Equilibrium and Resilience

Bacteriophages are viruses that can selectively infect specific species and strains of bacteria. Some bacterial species in the human gut have been negatively associated with gut health and skin health. This study is designed to measure the efficacy of two different bacteriophage-based treatments for 4 weeks to improve gut and skin health. These treatments are bacteriophage that target specific strains of Escherichia coli and Staphylococcus Aureus.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Colorado State University

Fort Collins, Colorado, 80523, United States

Location status: Recruiting

Location contact

Tiffany Weir, PhD

CONTACT

[email protected]

970-215-7571

Tiffany Weir, PhD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Between 18-75 years old
  • BMI <30
  • Experiencing mild-moderate gastrointestinal distress/ abdominal pain, bloating, constipation, and/or diarrhea

Exclusion criteria

  • Younger than 18 years old or greater than 75 years old
  • BMI >29.9
  • Antibiotic use in the past 2 months
  • Use of statins, metformin, prescription NSAIDs, and MAO inhibitors, or other medications that could interfere with study outcomes, as determined by the study PI
  • Current diagnosis of cancer, liver or kidney disease, gastrointestinal diseases, or cardiometabolic disease (diabetes, cardiovascular disease)
  • Individuals with allergies to capsule ingredients
  • Pregnant or breastfeeding individuals
  • Excess alcohol consumption (≥4 drinks on any given occasion and/or ≥8 drinks/week for women, and ≥5 drinks on any given occasion and/or ≥15 drinks/week for men)
  • Use of dietary supplements that contain probiotics or phages
  • Actively trying to lose weight
  • Participation in other research studies that would interfere with study endpoints or compliance
  • Unable or unwilling to consume capsules, provide stool or blood samples, track bowel movements and symptoms, and attend scheduled clinic visits

Treatment and study plan

Bacteriophages - MuniPhage

Dietary Supplement

1 x 106 Plaque Forming Units (PFU) of bacteriophage strains PBH34, CAH57, BFX121, and DNK95

Other names: MuniPhage

Bacteriophages - RenuPhage

Dietary Supplement

1 x 106 PFU of phage strains LG91, BD117, CD007, and PD23

Other names: RenuPhage

Placebo

Other

Rice maltodextrin

Primary outcomes

  1. Gastrointestinal Symptom Rating Scale

    Time frame: 4 weeks

    The gastrointestinal symptom rating scale is a widely used tool for measuring gastrointestinal symptoms across five domains.

Study contacts

Contact information is provided by the study sponsor or research team.

Jenny Whittington, MS

CONTACT

[email protected]

970-310-6843

Tiffany Weir, PhD

CONTACT

[email protected]

970-215-7571

Sponsors and collaborators

Lead sponsor

Colorado State University

Other

Registry information

Official study title

Phage-CLEAR: Phage-based Control and Limitation of Pathobionts for Microbiome Equilibrium and Resilience

Acronym: Phage-CLEAR

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Sep 14, 2026
Registry last updated
Sep 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.